Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren
Pm4.5
Piracetam – Forschung
Hilft wahrscheinlich
108 begutachtete Studien
Was die Evidenz sagt
Hilft wahrscheinlich
Piracetam scheint in 3 von 4 Studien mit messbaren Effekten zu helfen — die Evidenz tendiert klar ins Positive.
Die meiste Evidenz stammt aus hochwertigen Meta-Analysen und randomisierten Studien, veröffentlicht 1976–2026 mit einer typischen Studiengröße von 243 Teilnehmenden.
Basierend auf 108 Studien · 12 Meta-Analysen · 88 RCTs · 59,800 Teilnehmende insgesamt
Konfidenz
Hohe Konfidenz
Was die Studien gefunden haben
3geholfen1unklar· 104 weitere ohne bewertete Effektdaten
Nach Outcome
Cognitive functionKlassisches Nootropikum, das das Gedächtnis über die Modulation von AMPA-Rezeptoren verbessert · 2-4 weeks
Hilft vermutlich95 Studien
Therapeutic & clinical
Überwiegend Mechanismus / Beobachtung22 Studien
Neuroprotection & brain aging
Überwiegend Mechanismus / Beobachtung15 Studien
Heart & blood pressure
Überwiegend Mechanismus / Beobachtung15 Studien
Safety profile
Überwiegend Mechanismus / Beobachtung8 Studien
Recovery
Überwiegend Mechanismus / Beobachtung4 Studien
In Zahlen
Aus 15 Studien mit messbaren Effekten gezogen
Wahrscheinlich echte Effekte
67%
über Studien hinweg
Untersuchte Personen
60k
typische Studie: 243 Personen
Stärkste Designs
100
12 gepoolt, 88 randomisiert
Zeigte Nutzen
75%
3/4 Studien
Wie lange Studien liefen
1–3 Monate
1
Untersuchte Populationen
Dementia patients1
Patients with frontotemporal dementia1
Sickle cell disease patients1
Patients with schizophrenia1
Lässt nach
Nur 7 Studien in den letzten 5 Jahren · Neueste Meta-Analyse: 2025
197620012026
1Cognitive dysfunction in dementiaMeta-Analysen=44,854 · very large study2018
Einfach gesagt: The most effective intervention for dementia available is symptomatic treatment for vascular dementia.
Perng CH et al. · Psychopharmacology (2018)
Spürbar Nutzen
← SchlechterKein EffektBesser →
The pooled standardized mean difference of the treatment effects on cognitive dysfunction was 0.439 (95% confidence interval 0.374, 0.504).
The most effective intervention for dementia available is symptomatic treatment for vascular dementia.
Antipsychotic treatment for dementia alleviates cognitive dysfunction less effectively than does symptomatic treatment.
6Neuropsychiatric symptoms in frontotemporal dementiaMeta-Analysen=243 · medium study2023
Einfach gesagt: This study provides the first NMA for clinical recommendation to support the use of high-dose oxytocin and caution regarding the use of piracetam for neuropsychiatric symptoms in patients with FTD.
Huang MH et al. · The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry (2023)
Sehr groß Nutzen
← SchlechterKein EffektBesser →
Likely real
Compared with placebo, high-dose oxytocin (72 international units) was associated with the greatest improvement in patients' neuropsychiatric symptoms (SMD = -1.17, 95% CIs = -2.25 to -0.08, z = -2.10, p = 0.035).
Piracetam significantly worsened neuropsychiatric symptoms (SMD = 3.48, 95% CIs = 1.58 to 5.37, z = 3.60, p < 0.001) and caregiver stress (SMD = 2.40, 95% CIs = 0.80-4.01, z = 2.94, p = 0.003).
Trazodone had significantly higher rates of adverse events (OR = 9.53, 95% CIs = 1.85-49.20, z = 2.69, p = 0.007).
7Painful sickle cell disease crisesMeta-Analysen=169 · medium study2016
Einfach gesagt: The small number of included trials and their poor methodological quality provided insufficient reliable evidence to support the routine use of this medication for preventing the incidence of painful sickle cell disease crises.We will continue to run searches to identify any potentially relevant trials; however, we do not plan to update other sections of the review until new trials are published.
Al Hajeri A et al. · The Cochrane database of systematic reviews (2016)
Although there was no significant difference between the piracetam and placebo periods for the number of days of hospitalisation (P = 0.87) in one trial, inconsistencies in the criteria necessary for hospitalisation during sickle crises did not permit accurate conclusions to be drawn.
8Schizophrenia symptom severityMeta-Analysen=270 · medium study2019
Einfach gesagt: Some, but not all agents with anti-inflammatory properties showed efficacy.
Çakici N et al. · Psychological medicine (2019)
Spürbar Nutzen
← SchlechterKein EffektBesser →
The results of aspirin [mean weighted effect size (ES): 0.30; n = 270; 95% CI (CI) 0.06-0.54], estrogens (ES: 0.78; n = 723; CI 0.36-1.19), minocycline (ES: 0.40; n = 946; CI 0.11-0.68), and NAC (ES: 1.00; n = 442; CI 0.60-1.41) were significant in meta-analysis of at least two studies.
Some, but not all agents with anti-inflammatory properties showed efficacy.
Effective agents were aspirin, estrogens, minocycline, and NAC.
Einfach gesagt: High-level evidence related to pharmacological strategies for managing Lewy body dementia is rare.
Stinton C et al. · The American journal of psychiatry (2015)
High-level evidence related to pharmacological strategies for managing Lewy body dementia is rare.
Strategies for important areas of need in Lewy body dementia, such as autonomic symptoms and caregiver burden, have not been investigated, nor have the views of patients and caregivers about pharmacological strategies.
13Memory enhancementMeta-Analysen=886 · large study2024
Einfach gesagt: This investigation serves as a significant contribution to the ongoing quest to elucidate the potential benefits of piracetam in the field of cognitive neuroscience.
Gouhie FA, Barbosa KO, Cruz ABR, Wellichan MM, Zampolli TM. · Clinical neurology and neurosurgery (2024)
Kein klarer Effekt
← SchlechterKein EffektBesser →
Could be chance
Results In our analysis, 199 articles were identified, of which we included eighteen studies, comprising a total of 886 patients, of which Piracetam was the treatment option in 442 (49.88 %) patients.
Memory enhancement (SMD 0.75; 95 % CI [-0.19; 1.69]; p=0.12; I²=96 %) had no clinical difference between the intervention and the control group.
Conclusion Upon the conclusion of this study, it is apparent that we cannot definitively ascertain the impact of piracetam on memory function.